Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H8N2O2S.CH3O3S.Na |
| Molecular Weight | 290.292 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CS([O-])(=O)=O.NC1=CC=C(C=C1)S(N)(=O)=O
InChI
InChIKey=BSIXAEHVYKHWGJ-UHFFFAOYSA-M
InChI=1S/C6H8N2O2S.CH4O3S.Na/c7-5-1-3-6(4-2-5)11(8,9)10;1-5(2,3)4;/h1-4H,7H2,(H2,8,9,10);1H3,(H,2,3,4);/q;;+1/p-1
| Molecular Formula | CH3O3S |
| Molecular Weight | 95.098 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H8N2O2S |
| Molecular Weight | 172.205 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
63.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5636244/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.37% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5636244/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
15 % 1 times / day steady, topical Recommended Dose: 15 %, 1 times / day Route: topical Route: steady Dose: 15 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
Other AEs: Local reaction... Other AEs: Local reaction (0.2%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Local reaction | 0.2% | 15 % 1 times / day steady, topical Recommended Dose: 15 %, 1 times / day Route: topical Route: steady Dose: 15 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. | 2004-11-01 |
|
| Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides. | 2004-10-15 |
|
| Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats. | 2004-10-04 |
|
| Drinking-water nitrate, methemoglobinemia, and global burden of disease: a discussion. | 2004-10 |
|
| Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum. | 2004-09 |
|
| Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection. | 2004-08-20 |
|
| 4-sulphamoylphenyl semicarbazones with anticonvulsant activity. | 2004-08 |
|
| Sorption of sulfonamide pharmaceutical antibiotics on whole soils and particle-size fractions. | 2004-07-16 |
|
| Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design. | 2004-07-16 |
|
| Lessons unlearned. | 2004-07-06 |
|
| Effects of pig slurry on the sorption of sulfonamide antibiotics in soil. | 2004-07 |
|
| Glucose 6 phosphate dehydrogenase deficiency in adults. | 2004-07 |
|
| Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy. | 2004-06 |
|
| Emerging issues in infective endocarditis. | 2004-06 |
|
| Contamination of honey by the herbicide asulam and its antibacterial active metabolite sulfanilamide. | 2004-06 |
|
| Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. | 2004-06 |
|
| Defective DNA repair as a potential mechanism for the rapid development of drug resistance in Plasmodium falciparum. | 2004-05-04 |
|
| Simultaneous determination of cefatrizine and clavulanic acid in dog plasma by HPLC. | 2004-04-01 |
|
| An experimental animal model of aseptic loosening of hip prostheses in sheep to study early biochemical changes at the interface membrane. | 2004-03-03 |
|
| Synthesis and cytotoxic activity of lipophilic sulphonamide derivatives of the benzo[b]thiophene 1,1-dioxide. | 2004-03-01 |
|
| [Preparation of monoclonal antibody against sulfadiazine and development of an ELISA kit]. | 2004-03 |
|
| Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. | 2004-03 |
|
| Effects of polymorphic differences for sulfanilamide, as seen through 13C and 15N solid-state NMR, together with shielding calculations. | 2004-03 |
|
| Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. | 2004-02-26 |
|
| Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. | 2004-02-23 |
|
| Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. | 2004-02-09 |
|
| A new method for purification of carbonic anhydrase isozymes by affinity chromatography. | 2004-02 |
|
| Engineering of a broad specificity antibody for simultaneous detection of 13 sulfonamides at the maximum residue level. | 2004-01-14 |
|
| Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. | 2004-01-05 |
|
| High-performance liquid chromatography/inductively coupled plasma mass spectrometry and tandem mass spectrometry for the detection of carbon-containing compounds. | 2004 |
|
| Integron analysis and genetic mapping of antimicrobial resistance genes in Salmonella enterica serotype Typhimurium. | 2004 |
|
| Risk factors for antibiotic resistance in Campylobacter spp. isolated from raw poultry meat in Switzerland. | 2003-12-09 |
|
| Sulphonamide resistance gene sul3 found in Escherichia coli isolates from human sources. | 2003-12 |
|
| Investigation of structural and dynamic features of the radicals produced in gamma irradiated sulfanilamide: an ESR study. | 2003-11-28 |
|
| Facilitation of addition-elimination reactions in pyrimidines and purines using trifluoroacetic acid in trifluoroethanol. | 2003-11-21 |
|
| [Treatment of sulfanilamide production wastewater by resin adsorption technique]. | 2003-11 |
|
| Drug-induced bilateral transient myopia with the sulphonamide sulphasalazine. | 2003-11 |
|
| Validated HPLC method for the determination of ranitidine in plasma. | 2003-10 |
|
| Synthesis and applications of poly(acryl p-aminobenzenesulfonamideamidine- p-aminobenzenesulfonylamide) chelating fiber for pre-concentrating and separating trace Bi(III), Hg(III), Au(III) and Pd(IV) from solution samples. | 2003-10 |
|
| Generation of group-specific antibodies against sulfonamides. | 2003-09-24 |
|
| Carbonic anhydrase inhibitors: inhibition of human and murine mitochondrial isozymes V with anions. | 2003-09-01 |
|
| [Treatment of patients with acute pneumonia]. | 2003-08-02 |
|
| Measurement of physiological S-nitrosothiols: a problem child and a challenge. | 2003-08 |
|
| Preserving the chromatographic integrity of high-speed supercritical fluid chromatography separations using time-of-flight mass spectrometry. | 2003-07-15 |
|
| Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. | 2003-07-07 |
|
| [Integrons and antimicrobial resistance gene cassettes in Shigella flexneri strains ]. | 2003-07 |
|
| [Adverse cutaneous reaction to celecoxib: 6 cases]. | 2003-05 |
|
| Early manifestation of nephropathy in rats with arterial calcinosis. | 2003-05 |
|
| Design and synthesis of fluorescent beta-cyclodextrins for the enantioselective sensing of alpha-amino acids. | 2003 |
|
| Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. | 2003 |
Sample Use Guides
One applicatorful (about 6g) intravaginally once or twice daily. Improvements in symptoms should
occur within a few days, but treatment should be continued for a period of 30 days.
Route of Administration:
Vaginal
Antimicrobial activity of sulfanilamide was tested with different bacterial and yeast strains. MIC values were 8 ug/ml for Listeria innocua, Escherishia coli and Pseudomonas aeruginosa; 16 ug/ml for Staphylococcus aureu and Candida albicans; 100 ug/ml for Botrytis cinerea and Fusarium oxysporum culmorum.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 14:55:39 GMT 2025
by
admin
on
Wed Apr 02 14:55:39 GMT 2025
|
| Record UNII |
5P7TK324BY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
164512883
Created by
admin on Wed Apr 02 14:55:39 GMT 2025 , Edited by admin on Wed Apr 02 14:55:39 GMT 2025
|
PRIMARY | |||
|
35915-69-6
Created by
admin on Wed Apr 02 14:55:39 GMT 2025 , Edited by admin on Wed Apr 02 14:55:39 GMT 2025
|
PRIMARY | |||
|
300000054010
Created by
admin on Wed Apr 02 14:55:39 GMT 2025 , Edited by admin on Wed Apr 02 14:55:39 GMT 2025
|
PRIMARY | |||
|
5P7TK324BY
Created by
admin on Wed Apr 02 14:55:39 GMT 2025 , Edited by admin on Wed Apr 02 14:55:39 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
